Facebook Twitter RSS Feed
 - Neon Heart

Six weeks if triple therapy to provide anticoagulation to patients treated with drug-eluting stents was not superior to six months, according to results of the ISAR-TRIPLE trial presented Sept. 15 at the Transcatheter Cardiovascular Therapeutics scientific session. Panelists suggested sample size was a problem.

 - Stent

Fractional flow reserve-guided side branch lesion stenting holds promise of fewer stents placed and more years between retreatment of stenosis, according to findings presented Sept. 14 at the Transcatheter Cardiovascular Therapeutics (TCT) conference.

 - hospital_doctor

Heparin is making a comeback in a big way, according to one statement made Sept. 14 at the Transcatheter Cardiovascular Therapeutics (TCT) conference. The speaker went on to say it will become the anticoagulant of choice over bivalirudin and others.

 - Radiation

WASHINGTON, D.C.—Use of a pelvic lead shield draped on a patient and a nonlead cap worn by an operator during coronary angiography reduced physician radiation exposure by more than 75 percent in a study presented Sept. 14 at the Transcatheter Cardiovascular Therapeutics scientific session.

 - clinical trial

Fewer patients with coronary artery disease who were treated with a bioresorbable scaffold experienced new or worsening angina after treatment than similar patients implanted with metal stents in the ABSORB II trial. The one-year results were presented Sept. 14 at the Transcatheter Cardiovascular Therapeutics scientific session.